Skip to main content
Erschienen in: Medical Oncology 2/2012

01.06.2012 | Original Paper

Aberrant microRNA expression in human cervical carcinomas

verfasst von: Qunxian Rao, Hui Zhou, Yongpai Peng, Jing Li, Zhongqiu Lin

Erschienen in: Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Because altered microRNAs (miRNAs) expression patterns have been observed in a variety of diseased tissues, miRNA expression was compared in human cervical cancer tissues relative to adjacent normal cervical tissues in the present study. Microarray chips with 924 probes were used to detect the expression of miRNAs in cervical cancer tissue and adjacent normal cervical tissue of 13 patients with cervical cancer (11 squamous cervical cancers, one cervical adenocarcinoma, and one cervical sarcoma), all of whom were infected with human papilloma virus (HPV) 16 and/or HPV18. Compared to the expression levels in normal cervical tissues, 18 miRNAs (1.9%) were significantly upregulated (increase of ≥2×), and 19 miRNAs (2.1%) were significantly downregulated (decrease of ≤0.5×) in cervical cancer tissues. miRNA expression was independent of lymph node involvement, vascular invasion, and pathological differentiation. Taken together, cervical cancer tissues have altered expression of miRNAs relative to adjacent normal tissues. Further studies are necessary to determine whether aberrant miRNA expression is related to the pathogenesis of cervical cancer.
Literatur
1.
2.
Zurück zum Zitat Lecellier CH, et al. A cellular microRNA mediates antiviral defense in human cells. Sci. 2005;308:557–60.CrossRef Lecellier CH, et al. A cellular microRNA mediates antiviral defense in human cells. Sci. 2005;308:557–60.CrossRef
3.
Zurück zum Zitat O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc–regulated microRNAs modulate E2F1 expression. Nat. 2005;435:839–43.CrossRef O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc–regulated microRNAs modulate E2F1 expression. Nat. 2005;435:839–43.CrossRef
4.
Zurück zum Zitat Thomson JM, Parker J, Perou CM, Dang CV, Mendell JT. A custom microarray platform for analysis of microRNA gene expression. Nat Methods. 2004;1:47–53.PubMedCrossRef Thomson JM, Parker J, Perou CM, Dang CV, Mendell JT. A custom microarray platform for analysis of microRNA gene expression. Nat Methods. 2004;1:47–53.PubMedCrossRef
5.
Zurück zum Zitat Barad O, et al. MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues. Genome Res. 2004;14:2486–94.PubMedCrossRef Barad O, et al. MicroRNA expression detected by oligonucleotide microarrays: system establishment and expression profiling in human tissues. Genome Res. 2004;14:2486–94.PubMedCrossRef
6.
Zurück zum Zitat Sullivan CS, Grundhoff AT, Tevethia S, Pipas JM, Ganem D. SV40-encoded microRNAs regulate viral gene expression and reduce susceptibility to cytotoxic T cells. Nat. 2005;435:682–6.CrossRef Sullivan CS, Grundhoff AT, Tevethia S, Pipas JM, Ganem D. SV40-encoded microRNAs regulate viral gene expression and reduce susceptibility to cytotoxic T cells. Nat. 2005;435:682–6.CrossRef
7.
Zurück zum Zitat Gupta A, Gartner JJ, Sethupathy P, Hatzigeorgiou AG, Fraser NW. Anti-apoptotic function of a microRNA encoded by the HSV-1 latency-associated transcript. Nat. 2006;442:82–5. Gupta A, Gartner JJ, Sethupathy P, Hatzigeorgiou AG, Fraser NW. Anti-apoptotic function of a microRNA encoded by the HSV-1 latency-associated transcript. Nat. 2006;442:82–5.
8.
Zurück zum Zitat Burnside J, et al. Marek’s disease virus encodes microRNAs that map to meq and the latency-associated transcript. J Virol. 2006;80:8778–86.PubMedCrossRef Burnside J, et al. Marek’s disease virus encodes microRNAs that map to meq and the latency-associated transcript. J Virol. 2006;80:8778–86.PubMedCrossRef
9.
Zurück zum Zitat Calin GA, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 2004;101:2999–3004.PubMedCrossRef Calin GA, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA. 2004;101:2999–3004.PubMedCrossRef
10.
Zurück zum Zitat Walboomers JM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.PubMedCrossRef Walboomers JM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.PubMedCrossRef
11.
Zurück zum Zitat Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244–65.PubMedCrossRef Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244–65.PubMedCrossRef
12.
Zurück zum Zitat Nambaru L, Meenakumari B, Swaminathan R, Rajkumar T. Prognostic significance of HPV physical status and integration sites in cervical cancer. Asian Pac J Cancer Prev. 2009;10:355–60.PubMed Nambaru L, Meenakumari B, Swaminathan R, Rajkumar T. Prognostic significance of HPV physical status and integration sites in cervical cancer. Asian Pac J Cancer Prev. 2009;10:355–60.PubMed
13.
Zurück zum Zitat Wang X, et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE 2008;e2557. Wang X, et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE 2008;e2557.
14.
Zurück zum Zitat Pang RT, et al. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis. 2010;31:1037–44.PubMedCrossRef Pang RT, et al. MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis. 2010;31:1037–44.PubMedCrossRef
15.
Zurück zum Zitat Martinez I, et al. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene. 2008;27:2575–82.PubMedCrossRef Martinez I, et al. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene. 2008;27:2575–82.PubMedCrossRef
16.
Zurück zum Zitat Wald AI, Hoskins EE, Wells SI, Ferris RL, Khan SA. Alteration of microRNA profiles in squamous cell carcinoma of the head and neck cell lines by human papillomavirus. Head Neck 2010 Jul 22 [Epub ahead of print]. Wald AI, Hoskins EE, Wells SI, Ferris RL, Khan SA. Alteration of microRNA profiles in squamous cell carcinoma of the head and neck cell lines by human papillomavirus. Head Neck 2010 Jul 22 [Epub ahead of print].
17.
Zurück zum Zitat Zhou X, et al. Polymorphisms involved in the miR-218-LAMB3 pathway and susceptibility of cervical cancer, a case-control study in Chinese women. Gynecol Oncol. 2010;117:287–90.PubMedCrossRef Zhou X, et al. Polymorphisms involved in the miR-218-LAMB3 pathway and susceptibility of cervical cancer, a case-control study in Chinese women. Gynecol Oncol. 2010;117:287–90.PubMedCrossRef
18.
Zurück zum Zitat Hu X, et al. A microRNA expression signature for cervical cancer prognosis. Cancer Res. 2010;70:1441–8.PubMedCrossRef Hu X, et al. A microRNA expression signature for cervical cancer prognosis. Cancer Res. 2010;70:1441–8.PubMedCrossRef
19.
Zurück zum Zitat Zhang Y, et al. Microarray profile of micro-ribonucleic acid in tumor tissue from cervical squamous cell carcinoma without human papillomavirus. Obstet Gynaecol Res. 2009;35:842–9.CrossRef Zhang Y, et al. Microarray profile of micro-ribonucleic acid in tumor tissue from cervical squamous cell carcinoma without human papillomavirus. Obstet Gynaecol Res. 2009;35:842–9.CrossRef
20.
Zurück zum Zitat Gao C, et al. Reduced microRNA-218 expression is associated with high nuclear factor kappa B activation in gastric cancer. Cancer. 2010;116:41–9.PubMedCrossRef Gao C, et al. Reduced microRNA-218 expression is associated with high nuclear factor kappa B activation in gastric cancer. Cancer. 2010;116:41–9.PubMedCrossRef
21.
Zurück zum Zitat Wu W, Lin Z, Zhuang Z, Liang X. Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev. 2009;18:50–5.PubMedCrossRef Wu W, Lin Z, Zhuang Z, Liang X. Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. Eur J Cancer Prev. 2009;18:50–5.PubMedCrossRef
22.
Zurück zum Zitat Chou YT, et al. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res. 2010;70:8822–31.PubMedCrossRef Chou YT, et al. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res. 2010;70:8822–31.PubMedCrossRef
23.
Zurück zum Zitat Chen H, et al. miR-7 and miR-214 are specifically expressed during neuroblastoma differentiation, cortical development and embryonic stem cells differentiation, and control neurite outgrowth in vitro. Biochem Biophys Res Commun. 2010;394:921–7.PubMedCrossRef Chen H, et al. miR-7 and miR-214 are specifically expressed during neuroblastoma differentiation, cortical development and embryonic stem cells differentiation, and control neurite outgrowth in vitro. Biochem Biophys Res Commun. 2010;394:921–7.PubMedCrossRef
24.
Zurück zum Zitat Sarkar FH, Li Y, Wang Z, Kong D, Ali S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat. 2010;13:57–66.PubMedCrossRef Sarkar FH, Li Y, Wang Z, Kong D, Ali S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat. 2010;13:57–66.PubMedCrossRef
25.
Zurück zum Zitat Blenkiron C, et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 2007;8:R214.PubMedCrossRef Blenkiron C, et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol. 2007;8:R214.PubMedCrossRef
26.
Zurück zum Zitat Raponi M, et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009;69:5776–83.PubMedCrossRef Raponi M, et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009;69:5776–83.PubMedCrossRef
27.
Zurück zum Zitat Pereira PM, Marques JP, Soares AR, Carreto L, Santos MA. MicroRNA expression variability in human cervical tissues. PLoS One. 2010;5:e11780.PubMedCrossRef Pereira PM, Marques JP, Soares AR, Carreto L, Santos MA. MicroRNA expression variability in human cervical tissues. PLoS One. 2010;5:e11780.PubMedCrossRef
Metadaten
Titel
Aberrant microRNA expression in human cervical carcinomas
verfasst von
Qunxian Rao
Hui Zhou
Yongpai Peng
Jing Li
Zhongqiu Lin
Publikationsdatum
01.06.2012
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2012
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-011-9830-2

Weitere Artikel der Ausgabe 2/2012

Medical Oncology 2/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.